Showing results (1-10 of 74) with videos related to
Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancerS Baka, M Ranson, P Lorigan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.Cancer Treatment Reviews|September 8, 2001
Gender and survival in malignant tumoursR Molife, P Lorigan, S MacNeilCancer Treatment Reviews|October 5, 2002
Tamoxifen ("Nolvadex"): a reviewM Clemons, S Danson, A HowellThe Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|December 1, 2004
Hormonal and genetic risk factors for breast cancerA Clamp, S Danson, M ClemonsAnnals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2010
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trialsP Wheatley-Price, F Blackhall, S-M Lee, et al.Lung Cancer (Amsterdam, Netherlands)|May 5, 2010
A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigueA Molassiotis, M Lowe, F Blackhall, et al.Current Cancer Drug Targets|January 29, 2008
IAPs as a target for anticancer therapyS Danson, E Dean, C Dive, et al.Cancer Treatment Reviews|April 26, 2001
Locoregionally recurrent breast cancer: incidence, risk factors and survivalM Clemons, S Danson, T Hamilton, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2014
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanomaA Gupta, S Love, A Schuh, et al.Pageof 8